tetra(4-n-methylpyridyl)porphine and Head-and-Neck-Neoplasms

tetra(4-n-methylpyridyl)porphine has been researched along with Head-and-Neck-Neoplasms* in 1 studies

Other Studies

1 other study(ies) available for tetra(4-n-methylpyridyl)porphine and Head-and-Neck-Neoplasms

Article	Year
Targeting of a hydrophilic photosensitizer by use of internalizing monoclonal antibodies: A new possibility for use in photodynamic therapy. International journal of cancer, 2000, Oct-01, Volume: 88, Issue:1 Coupling of photosensitizers to tumor-selective monoclonal antibodies (MAbs) is an attractive option for improving the selectivity of photodynamic therapy (PDT). For this purpose, hydrophilic sensitizers would be most suitable because of their solubility in water. However, such sensitizers are known to be ineffective in PDT, probably because they cannot readily pass the cell membrane and reach the critical intracellular target. We used the model compound TrisMPyP-PhiCO(2)H, a hydrophilic porphyrin derivative, to test the hypothesis that hydrophilic photosensitizers might become of therapeutic value when directed into the tumor cell by use of internalizing MAbs. TrisMPyP-PhiCO(2)H was conjugated using a labile ester. Conjugates showed no impairment of integrity on SDS-PAGE, full stability in serum in vitro, and optimal immunoreactivity when the sensitizer:MAb ratio was Topics: Animals; Antibodies, Monoclonal; Carcinoma, Squamous Cell; Chromatography, High Pressure Liquid; Electrophoresis, Polyacrylamide Gel; Head and Neck Neoplasms; Humans; Immunoconjugates; Iodine Radioisotopes; Isotope Labeling; Mice; Mice, Nude; Neoplasm Transplantation; Photochemotherapy; Photosensitizing Agents; Porphyrins; Tissue Distribution; Tumor Cells, Cultured	2000

Article

Year

Targeting of a hydrophilic photosensitizer by use of internalizing monoclonal antibodies: A new possibility for use in photodynamic therapy.

International journal of cancer, 2000, Oct-01, Volume: 88, Issue:1

Coupling of photosensitizers to tumor-selective monoclonal antibodies (MAbs) is an attractive option for improving the selectivity of photodynamic therapy (PDT). For this purpose, hydrophilic sensitizers would be most suitable because of their solubility in water. However, such sensitizers are known to be ineffective in PDT, probably because they cannot readily pass the cell membrane and reach the critical intracellular target. We used the model compound TrisMPyP-PhiCO(2)H, a hydrophilic porphyrin derivative, to test the hypothesis that hydrophilic photosensitizers might become of therapeutic value when directed into the tumor cell by use of internalizing MAbs. TrisMPyP-PhiCO(2)H was conjugated using a labile ester. Conjugates showed no impairment of integrity on SDS-PAGE, full stability in serum in vitro, and optimal immunoreactivity when the sensitizer:MAb ratio was

Topics: Animals; Antibodies, Monoclonal; Carcinoma, Squamous Cell; Chromatography, High Pressure Liquid; Electrophoresis, Polyacrylamide Gel; Head and Neck Neoplasms; Humans; Immunoconjugates; Iodine Radioisotopes; Isotope Labeling; Mice; Mice, Nude; Neoplasm Transplantation; Photochemotherapy; Photosensitizing Agents; Porphyrins; Tissue Distribution; Tumor Cells, Cultured

2000